Expressed sequence tag (EST), proteomic, and antibody capture assays are revealing a level of tear film protein complexity far greater than previously appreciated. A systems biology approach will be needed to fully appreciate function as tear protein doses fluctuate in time through different conditions. Although consensus is growing on what fully constitutes the human tear proteome, questions remain about the source and significance of the ϳ256 tear proteins designated as "intracellular." Many of these may derive from normal cellular turnover and could therefore be informative. A further Ͼ183 are designated as "extracellular." Surprisingly, only 4 to 5% of these appear to be dysregulated in the three forms of dry eye preliminarily examined to date. Some differ and a couple overlap, suggesting that disease-specific signatures could be identified. Future dry eye treatment might include recombinant tear protein rescue as a personalized ophthalmic approach to ocular surface disease. (Optom Vis Sci 2008;85:643-652) 
The Expanding Tear Proteome E arly study of tears by SDS-polyacrylamide gel electrophoresis (PAGE) identified lysozyme (LYZ), lactotransferrin (LTF; lactoferrin), and lipocalin-1 (LCN1; von Ebner gland protein or tear specific prealbumin) that together constitute 70 to 85% of total tear protein. 1 Later, transferrin (TF), albumin (serum albumin), secretory IgA (CD79A), and lipophilin (PLP1) [1] [2] [3] [4] were identified, and more recently via immunoassays of increasing sensitivity and reliability 5 : phospholipid transfer protein, 6 growth factors, 7, 8 neurotrophic factors, 9 cytokines, 5,10 -13 matrix metalloproteinases (MMP), 11,14 -16 bradykinins, 17 tachykinins (e.g., substance P), 18, 19 fibronectin (FN1), 20 plasminogen activator, 21 defensins, 22 aquaporins, 23 phospholipase, 24 immunoglobulins, 25 lactate dehydrogenase, 26 proline-rich 4 (lacrimal) 27 and insulin. 8 Continuing efforts are underway to document the complete human tear film proteome by mass spectrometry. 28 -30 De Souza and co-workers identified almost 500 proteins in human closed eye tears using a ultra-high resolution hybrid linear trap-Fourier Transform and a linear ion trap-orbitrap approach. 29 A surprising number (ϳ256) are designated as "intracellular" proteins by Gene Ontology, suggesting that the process of normal epithelial turnover is a significant source. 31 Others may be contaminants of the method of collection. A further Ͼ183 are designated as "extracellular" (Table 1) . Preliminary indications primarily by 2-D PAGE are that a surprisingly small fraction (4 to 5%) of these are down-regulated in dry eye (*, ⌬, † in Table 1) . 28, 32, 33 This observation could set the stage for assays defining what is healthy, what is diseased, and possibly when disease has been initiated.
Functional Checks and Balances
Tear proteins contribute to the anti-microbial and anti-inflammatory defense of the exposed ocular surface. Some form heterocomplexes, and may function in normal epithelial growth, protein/fluid/electrolyte secretion and other aspects of normal ocular physiology. Few have been actually tested on ocular surface cells. Appreciating the true range of functional capacity and synergies will require a systems biology approach that integrates tear protein doses in time through different conditions. Following is a brief commentary on a selection of constituents from each Table 1 functional category with attention to ocular surface biology and dry eye when known. matrix collagen IV and V degradation S100A8 S100 calcium binding protein A8 22, 29 possible cytokine and inhibitor of casein kinase S100A9 S100 calcium binding protein A9 The capacity for "Angiogenesis" is highly regulated. Normal human tears contain the angiogenic promoters angiogenin and endothelial growth factor 1. Tears also contain the angiogenic inhibitors serpin peptidase inhibitor SERPINF1, brain-specific angiogenesis inhibitor 3, and the multifunctional cell adhesion protein thrombospondin 1 (THBS1; CellAdhesion/Motility/ Structure/). LTF ("Proteinase/Inhibitor/Antimicrobial") is antiangiogenic when fragmented. The primary inhibitor of corneal angiogenesis is soluble fms-related tyrosine kinase 1 that competes with vascular endothelial growth factor receptor (VEGR) for angiogenic vascular endothelial growth factor A (VEGF). Fms-related tyrosine kinase 1 is expressed throughout the corneal epithelium. 34 Most tear proteins in the "Biosynthesis" category are primarily intracellular. For example, mitochondrial adenosine triphosphate (ATP) synthase, Hϩ transporting, mitochondrial F1 complex, ␤-polypeptide (ATP5B) is a subunit of mitochondrial ATP synthase. The suggestion that ATP5B has an alternative plasmalemmal/extracellular location is interesting because it implicates a potential source of tear ATP. ATP and uridine triphosphate (UTP) target ocular surface P2Y purinergic receptors to stimulate the production and release of tear mucins and non-inflammatory heparanase.
35, 36 ␤-1,4-Galactosyltransferase is primarily associated with the Golgi apparatus, but its alternative plasmalemmal location is well-established. Here it promotes cell adhesion by binding galactosylated proteins such as laminins. 37 Numerous tear proteins are heavily galactosylated (i.e., mucins and proteoglycans) and are capable of binding ␤-1,4-galactosyltransferase. Peptidylprolyl isomerase (cyclophilin C) is most commonly associated with the endoplasmic reticulum where it binds cyclosporine A for immunosuppresive signaling. Its alternative extracellular location in tears may have relevance to the topical application of cyclosporine A for dry eye.
Intracellular "Calcium" signaling is fundamental to the normal function of ocular surface epithelia. Corneal or conjunctival calcification is respectively associated with phosphate in artificial tears 38 and elevated serum calcium in chronic renal failure. 39 Tear ␣-2-HS-glycoprotein is an inhibitor of calcification. Annexin A5 is a calciumdependent phospholipid binding protein that promotes corneal wound healing. 40 Although primarily cytoplasmic, Annexin A5 has an alternative plasmalemmal/extracellular location. Also in tears is the calcium binding protein calreticulin (CALR). CALR ligation of Sjogren's syndrome autoantigen Ro60 kDa enhances anti-Ro60 kDa autoantibody recognition. 41 CALR is alternatively plasmalemmal/extracellular, and primarily in the endoplasmic reticulum.
A number of "Carbohydrate" proteins are found in tears. Almost all are listed as primarily intracellular and alternatively extracellular or plasmalemmal. Two exceptions are the extracellular proteins chitinase 3-like 2 and lectin, galactoside-binding, soluble, 3 binding protein.
Glyceraldehyde-3-phosphate dehydrogenase has a newly identified extracellular role in the eye as a binding partner for TF. Interestingly glyceraldehyde-3-phosphate dehydrogenase expression is iron regulated. 42 Galectin-3 is a ␤-galactoside binding protein that plays a key role in corneal re-epithelialization after wounding, as revealed by use of galectin-3 null mice. 43 Enolase 1 (␣) is strongly expressed in basal cells of the limbus 44 and is up-regulated in keratoconus. Amylo-1, 6-glucosidase, 4-alpha-glucanotransferase (AGL) has hydrolase and transferase activity. Chitinase 3-like 2 has a particular affinity for glycans but has no apparent chitinase activity. Enolase 1 is glycolytic. Carbohydrate modification or binding can substantially alter or regulate function. One example is tear heparanase cleavage of heparan sulfate on cell surface syndecan-1 for lacritin binding and signaling. 45 The extent to which carbohydrate modifying proteins regulate ocular surface physiology is not fully explored.
Tears are rich in "Carrier/Binding Protein/Steroid Assoc." proteins. Albumin is abundant in tears as a binding protein for free fatty acids and other elements of the tear film. ␣-2-Glycoprotein 1 functions in cell adhesion, antigen processing/presentation, immune response, and binds polyunsaturated fatty acids. 46 CD14 is an important cell surface co-receptor for bacterial lipopolysaccharide in innate immunity. CD14 on macrophages helps clear apoptotic cells. Deleted in malignant brain tumors is a secreted scavenger receptor cysteine-rich protein that plays a key role in terminal epithelial differentiation and when deleted in mice is embryonic lethal. 47 Two forms of the predicted twelve different deleted in malignant brain tumors isoforms have been detected in human tears. 48 Heparan sulfate proteoglycan 2 (HSPG2 or perlecan) is a binding partner for fibroblast growth factors (FGF's) and several extracellular matrix molecules. HSPG2 mutations in Schwartz-Jampel Syndrome are associated with myopia. 49 LCN1 scavenges a wide variety of lipids and potentially other hydrophobic compounds from tears. Some of this lipid content may derive from exudated ocular surface epithelia as part of the normal course of ocular surface epithelial renewal. LCN1 also has magnesium-dependent endonuclease activity. 50 TF delivers iron to cells via TF receptor uptake. By depleting extracellular iron, TF can limit bacterial growth. Thus these proteins contribute to the health and turnover of ocular surface epithelia.
Tear "Cell Adhesion/Motility/Structure" proteins are surprisingly diverse. Presence of the ubiquitous extracellular matrix/serum constituent FN1 brings a considerable cell adhesive capacity to tear film reflected in FN1's contribution to corneal wound healing. 51 Gesolin is a calcium-regulated protein more commonly associated with amyloidosis. Although its ocular surface role is unknown, it is differentially increased in keratoconus. 52 Laminin ␣-3 (LAMA3) chain is part of heterotrimeric laminin-5. Mutation in LAMA3 is associated with scarring of the conjunctiva. Laminin mediates corneal epithelial cell adhesion 53 and is primarily concentrated in basement membranes. Another tear constituent shared by extracellular matrices is the previously noted THBS1. THBS1 is highly expressed by corneal epithelial cells, particularly basal cells, is anti-angiogenic, and binds FN1 and heparan sulfate. Thus, the tear film has the compositional attributes of a highly disperse extracellular matrix.
The tear film is enriched by mitogens ("Cell Growth"), some with prosecretory activity. Angiopoietin-1, of the VEGF family, signals through Tie2 in bone marrow to help develop the hemopoietic stem cell niche. 54 Neovascularization following removal of limbal epithelia in mice involves angiopoietin-1 expression. 55 Epidermal growth factor (EGF) promotes tear secretion 56 and cell growth, and is expressed by both lacrimal acinar cells and basal cells of the corneal epithelium. Corneal epithelial cells respond to hepatocyte growth factor in cell proliferation assays suggesting partially shared signaling pathways with EGF. 57 Lacritin 58 promotes human corneal epithelial cell growth 59 and mucin 16 production (Wang and Laurie, unpublished), and appears to auto-stimulate tear protein secretion 60 by lacrimal acinar cells via ERK1/2-independent signaling. Lacritin employs a previously noted heparanase "on-switch" to bind syndecan-1 as a precursor to mitogenic signaling. 45 Lacritin is largely ocular-specific. Heparanase is
constitutively expressed by all layers of the normal corneal epithelium in mice, and has been implicated in glandular morphogenesis, epidermal stem cell migration, and cell survival. The transmembrane mucin 4 signals via its EGF domains and interacts with epidermal growth factor receptor (ERBB2) to promote cell differentiation and block apoptosis. 61 Several tear proteins promote neuronal survival including: glial cell derived neurotrophic factor, neurotropin 3 and neurotropin 5. This mitogenic/prosecretory capacity compensates for the lack of corneal blood supply and may help serve as a master growth regulator of the ocular surface and associated accessory organs.
The level of tear "Cytoprotective/Antiapoptotic" activity appears to be substantial. In addition to mucin 4, glial cell derived neurotrophic factor, neurotropin 3 and neurotropin 5 noted above, EGF (porcine photoreceptor), 62 hepatocyte growth factor (human corneal epithelial) 63 and lacritin (human corneal epithelial; Wang et al., unpublished) are each cytoprotective. Clusterin may help maintain the cornea as a non-keratinizing epithelium, 64 and is thought to act as an extracellular chaperone. Clusterin deficiency in the anterior segment of the eye is associated with pseudoexfoliation syndrome/glaucoma. 65 Mucin 16 on the surface of corneal epithelial cells is protective against Staphylococcus aureus bacterial binding. 66 Gel forming mucin 5AC is thought to help sweep the ocular surface of pathogens during blinking. Very little is known about putative protection from prolactin-inducible protein, proline-rich 1 (PROL1), and proline rich 4. A peptide from the N-terminus of PROL1 is an analgesic.
67
PROL1 binds the cell growth/maintenance protein statherin.
A number of tear proteins common to "Extracellular Matrix" have been noted above including: HSPG2, FN1, LAMA3, and THBS1. Others are: the collagen type VI ␣-1 chain, mucin-like 1, and SPARC-like 1 (SPARCL1). Collagen type VI ␣-1-polymerizes with COL6A2 and COL6A2 to form the microfibrillar collagen VI triple helix. Little is known about mucin-like 1. SPARCL1 influences extracellular matrix formation and is a negative regulator of cell proliferation. 68 Normal human tear chemokines and cytokines ("Immune") are extensive and varied. Chemokines include: chemokine (C-C motif) ligand 2, 4, 8, 11, 22 and 24 (CCL2 to 24) , chemokine (CXC motif) ligand 5, 9, 10 (CXCL5, 9, 10) and pro-platelet basic protein ligand 7. Cytokines include: interleukin 6, 8, 10, 12, 15, 16 (IL6 to 16) , interferon gamma and tumor necrosis factor (TNF). How the eye handles this normal chemokine/cytokine load is an important question. TNF in the presence of interferon gamma (IFNG) is for example inflammatory for the ocular surface and promotes epithelial death. Both IL6 and TNF are increased in tears of Sjögren's syndrome dry eye patients. 69 A full answer will require attention to dose and time, and the level of cytoprotection from cell growth and cytoprotective/anti-apoptotic factors. Helping in innate defense is complement component 3 (C3), a key player in activation of the complement activation pathways. Individuals deficient in C3 have increased risk of bacterial infection. C3 polymorphism is associated with age-related macular degeneration (AMD). Knockout of the C3 gene in C57BL/6.NOD-Aec1Aec2 mice reduced the onset of primary Sjögren's syndrome. 70 Complement factor H (CFH) regulates the alternative complement pathway. CFH polymorphism leading to decreased CFH activity is associated with increased risk of AMD. Oxidative stress decreases retinal CFH expression. 71 Oxidative stress is a consequence of dry eye. 72 The ocular innate "immune" defense mechanism is therefore primed for action. ). Tear APOA1 is reportedly up-regulated in diabetic retinopathy. 73 Phospholipid transfer protein binds heparin, is catalytically active in tears for phospholipid transfer and is thought to be involved in lipid clearance from the ocular surface, much like LCN1. 6 Prosaposin is a widely expressed lipid binding glycoprotein found in extracellular and lysosomal locations that is cleaved into four saposins involved in antigen presentation.
Among "Other/Unknown" proteins are angiotensinogen, ␤-2-microglobulin (B2M), three intriguing proteins with no known function and several others. B2M is associated with the major histocompatibility complex (MHC) class-I heavy chain on cell surfaces. Mice lacking ␤-2-microglobulin reject orthotopic corneal allografts like their C57BL/6 controls. 74 Several enzymes are highlighted in the "Phosphatase/Kinase/ GTPase/Other Enzyme" category. Ceruloplasmin is a copper binding protein involved in peroxidation of the iron metalloprotein TF. Deficiency is associated with retinal pigment degeneration linked with increase in iron. MMP9 is up-regulated in dry eye tears leading to increased corneal epithelial permeability and turnover. MMP9 Ϫ/Ϫ dry eye mice lack increased permeability and turnover. 75 Transglutaminase 2 is up-regulated in ultraviolet B (UVB) stimulated apoptosis of human corneal epithelial cells. Inhibition of Transglutaminase 2 suppresses apoptosis. 76 Tears contain a wide variety of "Proteinase/Inhibitor/Antimicrobial" proteins that play a key role in innate immune defense. ␣-2-Macroglobulin (A2M) is a broad-acting protease inhibitor. It also binds tear proteins B2M, cathepsin B (lysosomal cysteine protease) and IL10; and the growth factors nerve growth factor ␤-polypeptide, platelet-derived growth factor ␤-L-polypeptide and transforming growth factor ␤1. 77 This latter property, via interaction of A2M with its receptor LPR1, is thought to be involved in inhibiting proliferation of retinal glial cells. 78 Cystatin 4 is a cysteine proteinase inhibitor, likely serving a protective role on the ocular surface. LTF appears to have multiple roles. It reduces UV-B oxidative damage of human corneal epithelial cells, 79 it may be a general regulator of epithelial cell growth, it is antimicrobial and as previously noted when fragmented has anti-angiogenic activity. A Glu561Asp polymorphism is associated with corneal amyloidosis with trichiasis. 80 LTF binds tear proteins CD14, ceruloplasmin, LCN1, and LYZ. Also anti-bacterial are LCN1 (binds microbial iron chelating siderophores), 81 lactoperoxidase, LYZ (a hydrolase that cleaves bacterial cell wall ␤ (1 to 4) glycosidic linkages)), and the polymeric immunoglobulin receptor that binds to Streptococcus pneumoniae. This overlapping mechanism of proteinases and inhibitors appears to become unbalanced in dry eye.
Chloride intracellular channel 2 ("Receptor/Channel/Transport") regulates intracellular Cl Ϫ concentration in the trabecular meshwork cells. Its role on the ocular surface and in tears appears to be unknown.
Selective Tear Protein Loss in Dry Eye
Although Ͼ183 "extracellular" and ϳ256 "intracellular" proteins populate the tear proteome surprisingly few appear to change in dry eye (*, ⌬, † in Table 1) . 28, 32, 33 A discovery phase comparison of dry eye and normal tears is perhaps best done by sensitive silveror fluorescent-stained 2-D PAGE. This has advantages to an initial Dry Eye and Designer Ophthalmics-Laurie et al. 649 mass spectrometry step. Thus using 2-D PAGE, Koo et al. 28 detected eight distinct proteins down-regulated at least 50% in blepharitis vs. normal tears. Each down-regulated protein was identified by ESI-Q-TOF MS/MS (Table 1*). Down-regulation for some was verified by Western blotting. Similarly using 2-D differential gel electrophoresis of tears from contact lens-related dry eye vs. normals, Green-Church et al. 33 found only three tear proteins significantly decreased (Table 1 †) . Several others were increased. 33 Each was identified by nano-LC-MS/MS. Current problems with the use of mass spectrometry in the first step include differential ionization efficiency of analytes and a relatively narrow dynamic range. However, a SELDI study suggesting differences between Sjögren's syndrome and normal tears 82 was recently pursued in more depth by LC-MS/MS. Only seven proteins were down-regulated (Table 1⌬) . 32 One common link between the three studies is the down-regulation of lacritin, that as noted above functions as a prosecretory mitogen. 58 This intriguing pattern invites further study with larger sample numbers and sensitive immunoassays capable of quantitatively detecting low abundant tear proteins.
Recombinant Tear Protein Rescue
Is down-regulation of some tear proteins disease provoking? If so, tear proteins can be generated by recombinant DNA technology. 59 When mixed with vehicle, topical application could prove effective. Over the past 34 years since the discovery of recombinant DNA technology, an increasing number of human recombinant proteins have been successfully developed into therapeutics for the treatment of anemia, cancer, and renal, cardiovascular, rheumatologic and neurological diseases. Human recombinants include: erythropoietin, colony stimulating factor 3 (G-CSF), plasminogen activator, interferons, ILs, and humanized monoclonal antibodies. In AMD or rubeosis iridis, recombinant Avastin and the ocular-reformulated Lucentis have proven effective. Each is a humanized fragment of recombinant anti-VEGF monoclonal antibody. Similarly, uveitis can be treated by the recombinant Infliximab (humanized anti-TNF monoclonal antibody). All three are administered by intravitreal injection. Topically applied human recombinant interferon-gamma has shown efficacy for herpetic keratitis.
Recombinant human proteins are the most rapidly expanding class of therapeutics in human health care with an expected 2010 market value of $52 billion. 83 Each demands a strong translational research effort, and only a fraction of recombinant proteins make it to market. Issues include economy of manufacture and stability in an appropriate vehicle, purity/reproducibility and compliance with current Good Manufacturing Practices. Also, thorough preclinical animal testing of dose efficacy in dry eye models, demonstration of minimal topical and systemic adverse reactions or toxic effects, and definition of basic parameters of absorption, distribution and excretion. For an effective recombinant dry eye therapeutic, there should be evidence of active and preferably prolonged induction of basal tears. Tears of dry eye patients should be compositionally similar to normal tears and there should be no toxicity to ocular tissues. Administration would be topical and optimally coupled to an immunoassay. With a selection of human recombinant tear proteins or synthetic peptides available for reconstitution, one might have available a "designer" or personalized ophthalmic treatment regimen for dry eye. Although developing recombinant protein manufacturing processes are time-consuming and much remains to be learned about the cell biology of tear proteins, inducing or reconstituting a natural tear film may be the most satisfactory approach to dry eye.
